Status: Recruiting
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard treatment or standard treatment alone for 12 weeks.
Participants needed: 80
Trial details
Phase: Phase 4Age: 18-80Biological sex: AllType: InterventionalSponsor: EVD Pharmacy and Medical Company LimitedUpdated: Sep 30, 2026Locations: 1
Eligibility criteria
Male or female. [+6]
Hemorrhagic stroke. [+10]